FDA Commissioner Hamburg confirms she is resigning

6 February 2015
fda-big

After a day of rumor and speculation, late yesterday US Food and Drug Administration Commissioner Margaret Hamburg confirmed that she would be resigning from the post. After nearly six years as head of the agency, 59-year old Dr Hamburg will step down at the end of March.

“As you can imagine, this decision was not easy,” said Dr Hamburg, adding: “My tenure leading this agency has been the most rewarding of my career, and that is due in no small part to all of you - the dedicated and hard-working people that make up the heart of this agency. While there is still work ahead (and there always will be), I know that I am leaving the agency well-positioned to fulfill its responsibilities to the American public with great success.”

After outlining the many achievements of the FDA under her leadership, Dr Hamburg said: “I am confident that the leadership team that we have in place will enable FDA to capitalize on, and improve upon, the significant advances we’ve made over the last few years.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical